Abstract:TNBC accounts for about 15-20 percent of all breast cancer cases, with a high incidence in young and African-American women. TNBC lacks the expression of estrogen receptor, progesterone receptor, and normal human epidermal growth factor receptor type 2 (HER2) copy number with expression. Thus, TNBC is not sensitive to endocrine and targeted molecular therapies. Therefore, surgery and systemic chemotherapy are the primary treatment methods for TNBC. The adjuvant therapy regimen includes anthracycline, paclitaxel, or both in (Neo-) early TNBC. However, this treatment is often ineffective after recurrence or metastasis. Therefore, continuously searching for new targeted therapies and immunotherapies becomes a focus in TNBC treatment in patients with diverse communities. The studies showed that TNBC is more immunogenic than other subtypes of breast cancers with tumor-infiltrating lymphocytes (TILs) in its microenvironment. More importantly, Cytotoxic CD8+ TILs of the adaptive immune system are the most potent effectors in the anticancer immune response and constitute the backbone of cancer immunotherapy. Therefore, a high number of CD8+TILs in TNBC patients' tumors are considered a better prognosis following neoadjuvant chemotherapy. Hence, increasing and activating CD8+ TILs could be an exciting and appropriate approach to treating TNBC. Blocking immune checkpoints can inverse the microenvironment immunosuppressive state and enhance the function of tumor cell clearance. One of the major immune checkpoint therapies has involved a monoclonal antibody against programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1), expressed in various tumor cells, including TNBC and immune cells. The studies found that PD-1/PD-L1 negatively regulates CD8+ TILs in cancers, and blockade of PD-1 can induce CD8+ TILs responses in advanced melanoma. Interestingly, PD-1/PD-L1 immunotherapy has also progressed in suppressing TNBC growth and progression. However, the currently available immune checkpoint therapies have therapeutic limitations with the toxicity of the drugs. Thus, new therapeutic options are urgently needed. Our studies found that the expression of CCN5, an anti-invasive gene, correlates with the number of cytotoxic CD8+ TILs in ER+ and HER-2 positive breast cancer samples. Furthermore, we also observed that PD-L1 (programmed death-ligand 1), which was found to have high and low expression in MDA-MB-231 and 4T1, respectively, was suppressed in MDA-MB-231 and 4T1 TNBC cell lines by CCN5 recombinant protein treatment for 48 h. These findings might provide a novel immune checkpoint mechanistic explanation of CCN5 that mediates TNBC growth and progression suppression. Citation Format: Upasana Biswas, Anjali Kambhampati, Noor Haideri, Archana De, Sunil Upadhyay, Snigdha Banerjee, Sushanta Banerjee. The role of CCN5 in regulation of tumor-infiltrating lymphocytes (TILS) in triple-negative breast cancer (TNBC) cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1399.

Integrin α9 depletion promotes β‐catenin degradation to suppress triple‐negative breast cancer tumor growth and metastasis

Abstract 1116: the Role of ADAM9 and PI3K-dependent NF-kappa B Pathway in Promoting Metastasis of Triple-Negative Breast Cancer

ADAM9 Mediates Triple-Negative Breast Cancer Progression Via AKT/NF-κB Pathway.

Combined knockdown of CD151 and MMP9 may inhibit the malignant biological behaviours of triple-negative breast cancer through the GSK-3β/β-catenin-related pathway

BCL9/BCL9L Promotes Tumorigenicity Through Immune-Dependent and Independent Mechanisms in Triple Negative Breast Cancer

Isotoosendanin exerts inhibition on triple-negative breast cancer through abrogating TGF- β -induced EMT via directly targeting TGF β R1

CCT6A and Triple-Negative Breast Cancer Metastasis: Activating the AKT/MDM2/P53 Pathway

Ebag9 Inducing Hyporesponsiveness Of T Cells Promotes Tumor Growth And Metastasis In 4t1 Murine Mammary Carcinoma

Integrin α6β4 Upregulates PTPRZ1 Through UCHL1-Mediated Hif-1α Nuclear Accumulation to Promote Triple-Negative Breast Cancer Cell Invasive Properties

ITGA9: Potential Biomarkers and Therapeutic Targets in Different Tumors.

Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer

Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models

Chaperonin‐containing TCP1 Subunit 6A Inhibition Via TRIM21‐mediated K48‐linked Ubiquitination Suppresses Triple‐negative Breast Cancer Progression Through the AKT Signalling Pathway

The role of thrombomodulin in modulating ITGB3 expression and its implications for triple‐negative breast cancer progression

Tankyrases/β-catenin Signaling Pathway As an Anti-proliferation and Anti-metastatic Target in Hepatocarcinoma Cell Lines.

CRISPR/Cas9‑mediated EZH2 knockout suppresses the proliferation and migration of triple‑negative breast cancer cells

Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor

Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation

CD8 + T cell‐related KCTD5 contributes to malignant progression and unfavorable clinical outcome of patients with triple‐negative breast cancer

Abstract 1399: The role of CCN5 in regulation of tumor-infiltrating lymphocytes (TILS) in triple-negative breast cancer (TNBC) cells

Connexin 43 controls metastatic behavior in triple negative breast cancer through TGFβ1-Smad3-intergin αV signaling axis Based on optical image diagnosis